Highlights and Quick Summary
- Change in payables and accrued liability for the quarter ending September 30, 2023 was $2.68 Million (a 341.28% increase compared to previous quarter)
- Year-over-year quarterly Change in payables and accrued liability decreased by -34.37%
- Annual Change in payables and accrued liability for 2022 was $-25.9 Million (a -173.49% decrease from previous year)
- Annual Change in payables and accrued liability for 2021 was $35.2 Million (a 11557.62% increase from previous year)
- Twelve month Change in payables and accrued liability ending September 30, 2023 was $3.33 Million (a 116.43% increase compared to previous quarter)
- Twelve month trailing Change in payables and accrued liability decreased by -112.88% year-over-year
Trailing Change in payables and accrued liability for the last four month:
| 30 Sep '23 | 30 Jun '23 | 31 Mar '23 | 31 Dec '22 |
|---|---|---|---|
| $3.33 Million | $1.54 Million | $3.4 Million | $-25.9 Million |
Visit stockrow.com/PRME
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Change in payables and accrued liability of Prime Medicine, Inc.
Most recent Change in payables and accrued liabilityof PRME including historical data for past 10 years.Interactive Chart of Change in payables and accrued liability of Prime Medicine, Inc.
Prime Medicine, Inc. Change in payables and accrued liability for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | $2.68 | $0.61 | $-4.05 | – | – |
| 2022 | $4.09 | $0.89 | $2.47 | $-33.32 | $-25.87 |
| 2021 | – | – | – | $1.9 | $35.21 |
| 2020 | – | – | – | – | $0.3 |
Business Profile of Prime Medicine, Inc.
Sector: Healthcare
Industry: Biotechnology